Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma
D Berton-Rigaud… - International Journal of …, 2014 - ijgc.bmj.com
Carcinosarcomas (also known as malignant mixed müllerian tumors) are rare and highly
aggressive epithelial malignancies that contain both malignant sarcomatous and …
aggressive epithelial malignancies that contain both malignant sarcomatous and …
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix
T Satoh, Y Takei, I Treilleux… - International Journal of …, 2014 - ijgc.bmj.com
Small cell carcinoma of the cervix (SCCC) is a rare histological entity of uterine cervical
cancer. Compared with other common histological types, squamous cell carcinoma or …
cancer. Compared with other common histological types, squamous cell carcinoma or …
Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary
NS Reed, E Gomez-Garcia… - International Journal of …, 2014 - ijgc.bmj.com
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms most commonly
occurring in the gastrointestinal tract or the lungs. More frequent are gastrointestinal tumors …
occurring in the gastrointestinal tract or the lungs. More frequent are gastrointestinal tumors …
Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994.
G Kenter, S Greggi, I Vergote, D Katsaros, J Kobierski… - 2019 - ascopubs.org
5503 Background: Conflicting evidence on the value of neoadjuvant chemotherapy followed
by surgery compared to concomitant chemoradiation in Stage IB2-IIB cervical carcinoma led …
by surgery compared to concomitant chemoradiation in Stage IB2-IIB cervical carcinoma led …
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
H Sorbye, E Grande, M Pavel, M Tesselaar, N Fazio… - 2023 - bora.uib.no
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-
to-date and practical advice on the diagnosis and management of digestive neuroendocrine …
to-date and practical advice on the diagnosis and management of digestive neuroendocrine …
Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus
P Pautier, EJ Nam, DM Provencher… - International Journal of …, 2014 - ijgc.bmj.com
High-grade undifferentiated sarcomas (HGUSs) are rare uterine malignancies arising from
the endometrial stroma. They are poorly differentiated sarcomas composed of cells that do …
the endometrial stroma. They are poorly differentiated sarcomas composed of cells that do …
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers
NS Reed, P Pautier, E Ċvall-Lundqvist… - International Journal of …, 2014 - ijgc.bmj.com
Small cell carcinomas of the ovary are uncommon and account for less than 1% of ovarian
cancers. They were first recognized in 1979, and a number of reports appeared during the …
cancers. They were first recognized in 1979, and a number of reports appeared during the …
Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) …
V Ambrosini, M Caplin, JP Castaño… - Journal of …, 2024 - Wiley Online Library
Abstract Somatostatin receptor (SST) PET/CT is the gold standard for well‐differentiated
neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms …
neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms …
Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the …
J Capdevila, G Jimenez-Valerio, A Martinez… - 2021 - ascopubs.org
4113 Background: Predictive biomarkers of response to antiangiogenics currently remain
elusive, with several molecules discovered but not fully validated nor clinically applied …
elusive, with several molecules discovered but not fully validated nor clinically applied …
Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in …
Z Craig, J Swain, R Sharma, OO Faluyi, J Wadsley… - 2022 - ascopubs.org
293 Background: NET-02 was a multi-centre, randomised (1: 1), non-comparative phase II
trial of nal-IRI/5-FU/folinic acid (ARM A) or docetaxel (ARM B) in pts with progressive PD-EP …
trial of nal-IRI/5-FU/folinic acid (ARM A) or docetaxel (ARM B) in pts with progressive PD-EP …